News | Computer-Aided Detection Software | January 22, 2020

The final order reclassifies certain CADe devices from Class III to Class II devices, subject to premarket 510(k) notification

he U.S. Food and Drug Administration (FDA) has issued a final order to reclassify medical image analyzers applied to mammography breast cancer, ultrasound breast lesions, radiograph lung nodules and radiograph dental caries detection, postamendments class III devices (regulated under product code MYN), into class II (special controls), subject to premarket notification

Image courtesy of iCAD


January 22, 2020 — The U.S. Food and Drug Administration (FDA) has issued a final order to reclassify medical image analyzers applied to mammography breast cancer, ultrasound breast lesions, radiograph lung nodules and radiograph dental caries detection, postamendments class III devices (regulated under product code MYN), into class II (special controls), subject to premarket notification. These devices are intended to direct the clinician's attention to portions of an image that may reveal abnormalities during interpretation of patient radiology images by the clinician. FDA is also identifying the special controls that the Agency believes are necessary to provide a reasonable assurance of safety and effectiveness of the device type. The order will be effective Feb. 21, 2020. 

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, establishes a comprehensive system for the regulation of medical devices intended for human use. Section 513 of the FD&C Act (21 U.S.C. 360c) established three classes of devices, reflecting the regulatory controls needed to provide reasonable assurance of their safety and effectiveness. The three classes of devices are class I (general controls), class II (special controls), and class III (premarket approval).

Devices that were not in commercial distribution prior to May 28, 1976 (generally referred to as postamendments devices), are automatically classified by section 513(f)(1) of the FD&C Act into class III without any FDA rulemaking process. Those devices remain in class III and require premarket approval unless, and until, the device is reclassified into class I or II, or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the FD&C Act, to a predicate device that does not require premarket approval. The Agency determines whether new devices are substantially equivalent to predicate devices by means of premarket notification procedures in section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and part 807 (21 CFR part 807).

A postamendments device that has been initially classified in class III under section 513(f)(1) of the FD&C Act may be reclassified into class I or II under section 513(f)(3). Section 513(f)(3) of the FD&C Act provides that FDA acting by order can reclassify the device into class I or II on its own initiative, or in response to a petition from the manufacturer or importer of the device. To change the classification of the device, the proposed new class must have sufficient regulatory controls to provide a reasonable assurance of the safety and effectiveness of the device for its intended use.

On June 4, 2018 (83 FR 25598), FDA published in the Federal Register a proposed order to reclassify the device type from class III to class II, subject to premarket notification. The comment period on the proposed order closed on August 3, 2018.

You can read the full published final order here


Related Content

Videos | Information Technology

A discussion on macro trends and the future of medical imaging with Jef Williams, managing partner, Paragon Consulting ...

Time February 07, 2023
arrow
News | Radiation Therapy

February 2, 2023 — DenseBreast-info.org (DBI) announced the results of the study, “Effect of an Educational Intervention ...

Time February 02, 2023
arrow
News | Radiation Therapy

February 1, 2023 — Radiotherapy is a crucial component of cancer treatment, used to shrink or destroy tumors with high ...

Time February 01, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a recap of what ITN viewers found most interesting during the month of January: 1. A Look at the Changes in 2023 ...

Time February 01, 2023
arrow
Webinar | Information Technology

Postpandemic staffing shortages and increased volumes require radiologists to do more with less, exacerbating burnout ...

Time January 30, 2023
arrow
News | Digital Pathology

January 27, 2023 — Fujifilm has completed its asset purchase of Inspirata, Inc.’s digital pathology business effective ...

Time January 27, 2023
arrow
Videos | PACS

Konica Minolta Healthcare recently announced it is working with Amazon Web Services to offer its cloud-based Exa ...

Time January 27, 2023
arrow
News | Artificial Intelligence

January 26, 2023 — MedCognetics, Inc., an Artificial Intelligence (AI) software firm, announced that it has been awarded ...

Time January 26, 2023
arrow
News | Artificial Intelligence

Artificial intelligence (AI) is playing a growing role in all our lives and has shown promise in addressing some of the ...

Time January 26, 2023
arrow
News | Digital Pathology

January 25, 2023 — mTuitive, Inc. and PathPresenter Corporation announced a new partnership to deliver an enhanced ...

Time January 25, 2023
arrow
Subscribe Now